XTLbio Highlights Presence at The Liver Meeting
2003年10月28日 - 4:00PM
PRニュース・ワイアー (英語)
XTLbio Highlights Presence at The Liver Meeting XTLbio Highlights
Presence at The Liver Meeting HepeX Programs at 54th Annual AASLD
include Poster Presentations, Oral Presentation and Exhibitors
Booth Rehovot, Israel, 28 October 2003: XTL Biopharmaceuticals Ltd.
(LSE:XTL) provided details of key scientific presentations and data
released at the 54th Annual Meeting of The American Association for
the Study of Liver Diseases, October 24 - 28 in Boston,
Massachusetts. AASLD - The Liver Meeting -is the premier meeting in
the science and practice of hepatology where the cutting edge in
the study and treatment of liver and biliary disease is defined.
Highlights of XTLbio's presentations included the following: HCV
Small Molecule Program - Second New Drug Candidate advances to
preclinical development On Monday Oct 27, XTLbio's Chief Scientific
Officer, Dr. Shlomo Dagan delivered an Oral Presentation titled
IN-VITRO AND IN-VIVO EVALUATION OF HCV POLYMERASE INHIBITORS AS
POTENTIAL DRUG CANDIDATES FOR TREATMENT OF CHRONIC HEPATITIS C
INFECTION. Dr. Dagan reported that the Company has now advanced to
development a small-molecule drug candidate developed to inhibit
replication of the hepatitis C virus (HCV). The molecule, one of a
series of compounds licensed exclusively to XTLbio, has recently
shown good toxicity profiles in preliminary testing, thus advancing
it to the next level of pre-clinical development. As previously
announced, this family of HCV polymerase inhibitors exhibited
biological activity using XTLbio's proprietary HCV in vitro and in
vivo pre-clinical drug validation systems. Dr. Dagan also reported
that XTLbio's lead polymerase inhibitor remains on track for an IND
in 2004. HepeX-C Earlier this year XTLbio released preliminary data
regarding from its Phase 1b HepeX-C study. Poster Number 758:
CLINICAL EVALUATION OF A HUMAN MONOCLONAL ANTIBODY AGAINST THE
ENVELOPE PROTEIN (E2) OF HCV FOR PREVENTION OF HCV INFECTION
summarized the final study results and confirmed the clinical
activity of HepeX-C in chronic patients. Over 70% (18/25) of the
patients, had a greater than 80% decrease in HCV viral load
observed at least once following infusion, and one-third of the
patients showed a drop of between 1 log and 2.5 logs at least once
following infusion. HepeX-C continues to be well tolerated with no
drug related serious adverse effects. HepeX-B During 2002, XTL
released interim results from Phase 2a trial with HepeX-B and
lamivudine in patients with chronic HBV. Poster Presentation 781:
PHASE 2 CLINICAL STUDY EVALUATING SAFETY AND EFFICACY OF HEPEX-B, A
MIXTURE OF TWO HUMAN MONOCLONAL ANTIBODIES TO HBsAg IN COMBINATION
WITH LAMIVUDINE IN CHRONIC HBV PATIENTS reviewed the complete data
set from 60 patients, who were treated for periods up to one year.
HepeX-B was well tolerated and HBsAg levels were consistently
reduced across all patients and administrations. In some patients,
when HepeX-B was administered at a sufficient dose and frequency to
accomplish antibody excess - HBsAg was continuously suppressed for
prolonged periods - up to one year. Additionally, Poster 1773:
Viral Dynamics Modeling Indicates that THE MAJOR Mechanism of
Action of HepeX-B against Hepatitis B Virus is Acceleration of the
Free Virus Clearance was submitted by Prof. Avidan Neumann of Bar
Ilan University in collaboration with XTLbio. The poster provided
added evidence to support using HepeX-B to rapidly clear the virus
in patients. Contacts: XTLbio Dr. Martin Becker, President and CEO,
Tel: +972-8-930-4440 Glenn Kazo, CBO, Tel: +1-603-878-9857
Financial Dynamics David Yates, Sarah MacLeod, Tel: +44 (0) 20 7831
3113 About XTLbio XTL Biopharmaceuticals Ltd. (XTLbio) is a
biopharmaceutical company developing drugs against hepatitis.
XTLbio's HepeX� product line - now in clinical trials - has the
potential to introduce revolutionary therapies for viral hepatitis,
including prevention of re-infection in transplanted livers, the
Company's primary focus, and a longer-term cocktail approach in
treating chronic illness. XTLbio believes its primary competitive
advantage lies in its patented Trimera� technology, which enables
the development of fully human monoclonal antibodies and models of
human disease for pre-clinical drug validation. Established in
1993, XTLbio became a public company in 2000 with shares traded on
the London Stock Exchange under the symbol XTL. About hepatitis C
Hepatitis C is a major public health concern. The World Health
Organization estimates that 170 million people worldwide are
chronic carriers of the hepatitis C virus (HCV) and that 3 to 4
million people are newly infected each year. It is expected that 25
to 35% of these chronic patients will develop progressive liver
disease including cirrhosis and liver cancer. Hepatitis C is the
single leading cause of liver transplantation. The US Centres for
Disease Control and Prevention estimate that approximately 4
million people in the United States (almost 2% of the population)
have been infected with HCV, of whom, approximately 3 million are
chronically ill. Hepatitis C is the cause of an estimated 8,000 to
10,000 deaths annually in the US. About HCV-related liver
transplant prophylaxis Approximately 5% of chronic HCV patients
will develop end-stage liver disease, and ultimately may require
liver transplantation. Today, there is a major problem associated
with HCV-related liver transplantation. Although the infected liver
- the major source of viral replication - has been removed,
free-floating virus in the patient's serum re-infects the healthy
transplanted liver in a matter of weeks. Disease progression in
re-infected patients is several times faster and, in many cases, a
re-transplant becomes necessary. At present, there is no available
solution to this problem. About the treatment of chronic hepatitis
C The existing first-line chronic HCV therapy is often associated
with a 50-60% success rate but it is limited by severe side
effects, including anaemia, fatigue, hair loss and depression. Due
to the relatively limited efficacy and toxicity of this treatment,
chronic HCV is still considered to be an unmet medical need, with
estimated worldwide annual sales for all products treating chronic
hepatitis C reaching US$4 billion in 2004. HepeX�, Trimera�, XTL�
and XTLbio� are trademarks of XTL Biopharmaceuticals Ltd. END
Copyright